You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Jaypirca ® (pirtobrutinib) tablets
50 mg,100 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Has Jaypirca® (pirtobrutinib) been studied in pediatric patients?
The safety and effectiveness of Jaypirca (pirtobrutinib) have not been established in pediatric patients.
Pirtobrutinib Use in Pediatric Patients
The safety and effectiveness of pirtobrutinib have not been established in pediatric patients.1
Enclosed Prescribing Information
Reference
1Jaypirca [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
Date of Last Review: October 22, 2025